Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma

Mauro Signorelli, Valentina Chiappa, Lucas Minig, Robert Fruscio, Patrizia Perego, Giovanna Caspani, Marco Battistello, Nicoletta Colombo

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Ovarian carcinosarcoma (OCS) is a rare malignancy associated with a poor prognosis. Platinum, anthracyclines, and alkylating agents are the most effective antiblastic drugs for treatment of gynecologic epithelial and stromal tumors. The aim of this study was to determine response rate and overall survival (OS) of patients with OCS who were treated with a combination of these 3 drugs. Methods: Forty-one women with OCS whowere referred to the Department of Gynecologic Oncology of San Gerardo Hospital in Monza and European Institute of Oncology in Milan, between January 1995, and December 2006, and treated with a combination regimen of cisplatin, adriamycin, and cyclophosphamide or a combination regimen containing of cisplatin, epirubicin, and ifosfamide plus granulocyte colony-stimulating factor were considered for this study. Results: Four women had OCS stage I; 7, stage II; 23, stage III; and 7, stage IV. Heterologous, homologous, and mixed stromal components were described in 17, 14, and 10 patients, respectively. Thirteen women were treated with a combination of cisplatin, adriamycin, and cyclophosphamide and 28 with a combination of cisplatin, epirubicin, and ifosfamide plus granulocyte colony-stimulating factor. Two women did not complete their treatment because of the rapid progression of their disease and severe toxicity. Among 22 women considered evaluable for response, 10 (46%) achieved a complete response and 3 (13%) achieved a partial response (global response rate, 59%). Overall progression-free survival was 11.8 months (range, 0.9Y96 months) and 13.8 and 10.1 months in stage IYII and IIIYIV, respectively (P = 0.13). Median OS was 20 months (range, 1Y123 months), not reached in stage IYII, and 19.7 months in stage IIIYIV (P = 0.07). No significant difference between homologous and heterologous sarcomatous components was observed (P = 0.95), whereas no significant trend of improved OS was noticed for stage IIICYIV with optimal debulking surgery (n = 9), compared with suboptimal cytored ction (n = 19; 32.6 vs 14.5 months, P = 0.14). Conclusion: The combination of anthracycline, alkylating agent, and cisplatin showed a good response rate but also a high toxicity. The prognosis of OCS remains poor. Optimal cytoreductionmay improve survival, but newanticancer drugs or more effective regimens are awaited.

Original languageEnglish
Pages (from-to)1142-1146
Number of pages5
JournalInternational Journal of Gynecological Cancer
Volume19
Issue number6
DOIs
Publication statusPublished - Aug 2009

Keywords

  • Alkylating agent
  • Anthracycline
  • Chemotherapy
  • Cytoreduction
  • Ovarian carcinosarcoma
  • Platinum

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Fingerprint

Dive into the research topics of 'Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma'. Together they form a unique fingerprint.

Cite this